Delivery Order SPE2DB22D2108-SPE2DB25FU5GL
- Not listed
- The Defense Logistics Agency awarded a $9,400.49 delivery order to AmerisourceBergen Drug Corp for HUMIRA (CF) Pen 40 mg/0.4 mL on July 29, 2025, with an ultimate completion date of July 30, 2025. This is a firm fixed-price, competitively awarded contract with no set-aside designation. The contractor will perform work at its corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract...
- The Defense Logistics Agency awarded a $2,416.05 firm fixed price delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of HUMIRA (CF) Pen 40 mg/0.4 mls, with completion scheduled for July 29, 2025. This non-competitive delivery order was placed against AmerisourceBergen's broader pharmaceutical supply contract vehicle and will be performed at the contractor's facility in Conshohocken, Pennsylvania. HUMIRA is a widely-used biologic medication for treating autoimmune...
- The Defense Logistics Agency awarded a delivery order valued at $9,166.50 to AmerisourceBergen Drug Corp for the supply of HUMIRA (CF) Pen 40 mg/0.4 mls, a pharmaceutical product used in the treatment of autoimmune conditions. This contract type represents a firm fixed price delivery order with no set-aside designation, indicating the award was made through open competition. The order was executed on July 21, 2025, with an ultimate completion date of July 22, 2025, and will be performed at...
- The Defense Logistics Agency awarded a $9,257.14 delivery order to AmerisourceBergen Drug Corp on July 25, 2025, for the supply of HUMIRA (adalimumab) prefilled pens, 40 mg/0.4 mL. This non-competitive, competitively awarded contract is structured as a firm fixed price delivery order with a completion date of July 28, 2025. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its pharmaceutical distribution...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a $2,265.90 delivery order on July 18, 2025, for HUMIRA (CF) Pen 40 mg/0.4 mls, with completion scheduled for July 21, 2025. This competitive award, issued under firm fixed pricing with no set-aside designation, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) vehicle with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The pharmaceutical product...
- The Defense Logistics Agency awarded a $3,776.50 firm fixed-price delivery order to AmerisourceBergen Drug Corp for HUMIRA (CF) Pen 40 mg/0.4 mls, with an ultimate completion date of July 23, 2025. This competitive award, issued on July 22, 2025, carries no set-aside designation and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and running through December 2026. The performance...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $3,021.20 on August 13, 2025, for the supply of HUMIRA (CF) Pen 40 mg/0.4 mL. This is a firm fixed-price, non-set-aside competitive award with a performance location in Conshohocken, Pennsylvania, and an ultimate completion date of August 14, 2025. The delivery order represents a single transaction under AmerisourceBergen's larger federal contract vehicle with the Defense Logistics Agency. This delivery...
- The Defense Logistics Agency awarded a delivery order valued at $1,132.95 to AmerisourceBergen Drug Corp for HUMIRA Pen 40 mg/0.8 mls on July 21, 2025, with a completion date of July 22, 2025. This firm fixed-price contract represents a non-set-aside competitive award for pharmaceutical supplies to support federal medical procurement needs. The work will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen...
- The Defense Logistics Agency awarded a $3,828.03 delivery order to AmerisourceBergen Drug Corp for HUMIRA (CF) Pen 40 mg/0.4 mL pharmaceutical supplies on July 21, 2025, with an ultimate completion date of July 22, 2025. This firm fixed-price, non-set-aside contract represents a child delivery order under AmerisourceBergen's broader Indefinite Delivery Contract vehicle with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The supplies will be...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 13, 2025, for the supply of HUMIRA (CF) Pen 40 mg/0.4 mls, a specialty pharmaceutical product used in the treatment of autoimmune conditions. This firm fixed-price delivery order, valued at $11,500.66, is scheduled for completion by August 14, 2025, with performance to be executed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The contract was competitively awarded with no set-aside...
- SPE2DB22D2108Indefinite Delivery Contract
- SPE2DB22D2108-SPE2DB25FU5GLDelivery Order
The Defense Logistics Agency awarded a $9,183.92 delivery order to AmerisourceBergen Drug Corp for HUMIRA (CF) Pen 40 mg/0.4 mls on July 29, 2025, with a completion date of July 30, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and represents a single delivery under AmerisourceBergen's broader pharmaceutical supply agreement with DLA. The product will be delivered to AmerisourceBergen's distribution facility in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's substantial Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026, which serves as the primary vehicle for global pharmaceutical support to military healthcare programs. As a major pharmaceutical distributor and critical federal medical procurement vendor, AmerisourceBergen supplies a comprehensive range of brand-name and generic medications, vaccines, and medical devices to support Defense Health Agency, U.S. Coast Guard, and other government healthcare systems. HUMIRA, an immunosuppressant medication used in treating autoimmune conditions, represents one of numerous specialty pharmaceutical products the company delivers through its DLA contracts to support military medical readiness and personnel healthcare needs.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $9.2k | 7/29/25 |